Acura OTC Stock Today

ACUR
 Stock
  

USD 0.01  0.00  0.00%   

Market Performance
0 of 100
Odds Of Distress
Over 96
Acura Pharma is selling at 0.01 as of the 25th of September 2022; that is No Change since the beginning of the trading day. The stock's lowest day price was 0.01. Acura Pharma has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Acura Pharma Cmn are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of July 2022 and ending today, the 25th of September 2022. Click here to learn more.
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. The company was incorporated in 1935 and is based in Palatine, Illinois. The company has 65.09 M outstanding shares of which 89.85 K shares are presently shorted by private and institutional investors with about 0.73 trading days to cover. More on Acura Pharma Cmn

Acura Pharma OTC Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Acura Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Acura Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Acura Pharma Cmn generated a negative expected return over the last 90 days
Acura Pharma Cmn has high historical volatility and very poor performance
Acura Pharma Cmn has some characteristics of a very speculative penny stock
Acura Pharma Cmn has a very high chance of going through financial distress in the upcoming years
The company currently holds 324 K in liabilities with Debt to Equity (D/E) ratio of 2.4, implying the company greatly relies on financing operations through barrowing. Acura Pharma Cmn has a current ratio of 0.84, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Acura Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Acura Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Acura Pharma Cmn sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Acura to invest in growth at high rates of return. When we think about Acura Pharma's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 2.25 M. Net Loss for the year was (1.15 M) with profit before overhead, payroll, taxes, and interest of 1.79 M.
Acura Pharma Cmn currently holds about 89 K in cash with (396 K) of positive cash flow from operations.
Roughly 19.0% of Acura Pharma shares are held by company insiders
CEO and President and DirectorRobert Jones
Average Analyst Recommendation
Analysts covering Acura Pharma report their recommendations after researching Acura Pharma's financial statements, talking to executives and customers, or listening in on Acura Pharma's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Acura Pharma Cmn. The Acura consensus assessment is calculated by taking the average forecast from all of the analysts covering Acura Pharma.
Strong Buy1 Opinion
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Acura Pharma's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellUndervalued
Acura Pharma Cmn [ACUR] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Nano-Cap' category with current market capitalization of 650.89 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Acura Pharma's market, we take the total number of its shares issued and multiply it by Acura Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Acura Pharma Cmn conducts business under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 65.09 M outstanding shares of which 89.85 K shares are presently shorted by private and institutional investors with about 0.73 trading days to cover. Acura Pharma Cmn currently holds about 89 K in cash with (396 K) of positive cash flow from operations.
Check Acura Pharma Probability Of Bankruptcy
Ownership
Acura Pharma Cmn retains a total of 65.09 Million outstanding shares. Acura Pharma Cmn shows 18.66 percent if its outstanding shares held by insiders and 18.66 percent owned by other corporate entities . Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Acura Ownership Details

Acura Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Acura Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Acura Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Acura Pharma's value.
InstituionSecurity TypeTotal SharesValue
Captrust Financial AdvisorsCommon Shares2450.0
Lenox Wealth Advisors LlcCommon Shares7800.0
View Acura Pharma Diagnostics

Acura Pharma Cmn Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Acura Pharma market risk premium is the additional return an investor will receive from holding Acura Pharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Acura Pharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Acura Pharma's alpha and beta are two of the key measurements used to evaluate Acura Pharma's performance over the market, the standard measures of volatility play an important role as well.

Acura Stock Against Markets

Picking the right benchmark for Acura Pharma otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Acura Pharma otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Acura Pharma is critical whether you are bullish or bearish towards Acura Pharma Cmn at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Acura Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run ETF Directory Now

   

ETF Directory

Find actively traded Exchange Traded Funds (ETF) from around the world
All  Next Launch Module

Acura Pharma Corporate Directors

Acura Pharma corporate directors refer to members of an Acura Pharma board of directors. The board of directors generally takes responsibility for the Acura Pharma's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Acura Pharma's board members must vote for the resolution. The Acura Pharma board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
George Ross - Independent DirectorProfile
Bruce Wesson - Independent DirectorProfile
Immanuel Thangaraj - Independent DirectorProfile
William Skelly - Independent DirectorProfile

Invested in Acura Pharma Cmn?

The danger of trading Acura Pharma Cmn is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Acura Pharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Acura Pharma. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Acura Pharma Cmn is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please continue to Trending Equities. You can also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for analysis

When running Acura Pharma Cmn price analysis, check to measure Acura Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acura Pharma is operating at the current time. Most of Acura Pharma's value examination focuses on studying past and present price action to predict the probability of Acura Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Acura Pharma's price. Additionally, you may evaluate how the addition of Acura Pharma to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Is Acura Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acura Pharma. If investors know Acura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acura Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Acura Pharma Cmn is measured differently than its book value, which is the value of Acura that is recorded on the company's balance sheet. Investors also form their own opinion of Acura Pharma's value that differs from its market value or its book value, called intrinsic value, which is Acura Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acura Pharma's market value can be influenced by many factors that don't directly affect Acura Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acura Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Acura Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acura Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.